Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024


Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights.

The webcast can be accessed under "Events and Presentations" on the Investors section of the Viridian website at viridiantherapeutics.com. To participate in the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference code 7373356. A replay of the webcast will be available following the completion of the event.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian's goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.


These press releases may also interest you

at 03:33
Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation of an extension of its contract with The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF)...

at 03:00
ALLCLEAR TRAVEL RESEARCH: ONE IN FOUR PEOPLE WITH MEDICAL CONDITIONS RISK INVALIDATING THEIR TRAVEL INSURANCE WHEN TRAVELLING ABROAD
One in four people with pre-existing medical conditions (25%) say they will not declare all of their medical conditions when buying travel insurance, with 40% of these only declaring what they are currently being treated for. Of those that would not...

at 03:00
Viewpoint Teams Up with Cedar Community to Explore the Evolution of Aging in a New Episode
Viewpoint, the esteemed educational program hosted by renowned actor Dennis Quaid, is proud to announce a collaboration with Cedar Community in West Bend, Wisconsin for an upcoming episode that will shed light on the evolving journey of aging. Set to...

at 02:43
Invitation to the presentation of Calliditas´s interim report January - March 2024
Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be...

at 02:39
Bioretec Ltd's business review January-March 2024: Controlled launch in the U.S. progresses
This announcement summarizes Bioretec Ltd's business review for January-March 2024. The complete business review is attached to this release as a PDF file and available on the company's website at...

at 01:50
SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch
SHL Telemedicine Ltd. ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it's SmartHeart® membership program in the US. This...

More news about Health...


News published on and distributed by: